SCHEMBL30367449

SCHEMBL30367449

c1ccc2nc3nc4ccccc4nc3nc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.71
ALDH1A1 P00352 5/20 0.56
HPGD P15428 3/20 0.56
KDM4E B2RXH2 3/20 0.56
GAA P10253 2/20 0.56
HSD17B10 Q99714 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
NQO2 P16083 3/20 0.53
GLA P06280 2/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NPC1 O15118 1/20 0.48
USP2 O75604 1/20 0.48
POLB P06746 1/20 0.48
CACNA1B Q00975 1/20 0.48
APBA1 Q02410 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ACHE P22303 1/20 0.47
CCNT1 O60563 1/20 0.46
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13156551 1.00 MAPT (0.71) MAPTALDH1A1HPGDKDM4EGAA
SCHEMBL13500415 0.85 MAPT (0.53) MAPTALDH1A1HPGDKDM4EGAA
Phenazine SCHEMBL27643128 0.84 MAPT (1.00) MAPTALDH1A1HPGDKDM4EGAA
Phenazine SCHEMBL29356959 0.84 MAPT (1.00) MAPTALDH1A1HPGDKDM4EGAA
Phenazine SCHEMBL9049 0.84 MAPT (1.00) MAPTALDH1A1HPGDKDM4EGAA
SCHEMBL2422494 0.81 MAPT (0.56) MAPTALDH1A1HPGDKDM4EGAA
Phenazine SCHEMBL20475337 0.80 MAPT (0.92) MAPTALDH1A1HPGDKDM4EGAA
Phenazine SCHEMBL22345160 0.80 MAPT (0.92) MAPTALDH1A1HPGDKDM4EGAA
Phenazine SCHEMBL20475326 0.80 MAPT (0.92) MAPTALDH1A1HPGDKDM4EGAA
Phenazine SCHEMBL10866237 0.80 MAPT (0.92) MAPTALDH1A1HPGDKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540228-B2 Cross linked surface coating and interfacial layer for a perovskite material photovoltaic device CUBICPV INC. (US) 2026-02-03 US disclosed
EP-4660349-A2 PEROVSKITE MATERIAL LAYER PROCESSING CubicPV Inc. (GB) 2025-12-10 EP disclosed
CN-119404620-A Ionic liquid perovskite device 立方光伏股份有限公司 2025-02-07 CN disclosed
CN-119136633-A Enhanced perovskite materials for photovoltaic devices 立方光伏股份有限公司 2024-12-13 CN disclosed
US-20240407247-A1 Multi-Junction Perovskite Material Devices CUBICPV INC. 2024-12-05 US disclosed
CN-113272311-B Enhanced perovskite materials for photovoltaic devices 亨特钙钛矿技术有限责任公司 2024-09-10 CN disclosed
CN-118592107-A Method for forming perovskite material layer 立方光伏股份有限公司 2024-09-03 CN disclosed
CN-118556111-A Lead chelating materials for perovskite devices 立方光伏股份有限公司 2024-08-27 CN disclosed
CN-118486550-A Mixed perovskite material processing 立方光伏股份有限公司 2024-08-13 CN disclosed
US-20240114766-A1 Cross Linked Surface Coating and Interfacial Layer for a Perovskite Material Photovoltaic Device CUBIC PEROVSKITE LLC 2024-04-04 US disclosed
US-20230357632-A1 IONIC LIQUID PEROVSKITE DEVICES CUBICPV INC. 2023-11-09 US disclosed
CN-115911370-A Novel negative electrode material for water-based battery, water-based battery and preparation method of water-based battery 广西电网有限责任公司电力科学研究院 2023-04-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540228-B2 Cross linked surface coating and interfacial layer for a perovskite material photovoltaic device HCN2, HCN1, BRSK1 MAPT 1812/4885ALDH1A1 2071/4885HPGD 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.